Innate Pharma S.A. (IPHA)
NASDAQ: IPHA
· Real-Time Price · USD
1.82
-0.02 (-1.09%)
At close: Sep 25, 2025, 3:55 PM
1.81
-0.55%
After-hours: Sep 25, 2025, 04:00 PM EDT
-1.09% (1D)
| Bid | 1.76 |
| Market Cap | 153.32M |
| Revenue (ttm) | 12.62M |
| Net Income (ttm) | -49.47M |
| EPS (ttm) | -0.65 |
| PE Ratio (ttm) | -2.8 |
| Forward PE | -2.91 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 1.85 |
| Volume | 27,187 |
| Avg. Volume (20D) | 12,788 |
| Open | 1.85 |
| Previous Close | 1.84 |
| Day's Range | 1.81 - 1.86 |
| 52-Week Range | 1.29 - 3.51 |
| Beta | 0.91 |
| Ex-Dividend Date | n/a |
About IPHA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IPHA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IPHA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsEarnings Surprise
Innate Pharma S.A. has released their quartely earnings
on Sep 17, 2025:
Innate Pharma S.A. is scheduled to release its earnings on
Mar 26, 2026,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
7 months ago
+20.62%
Innate Pharma shares are trading higher after the ...
Unlock content with
Pro Subscription
9 months ago
+29.25%
Innate Pharma shares are trading higher after the company announced its TELLOMAK Phase 2 trial of Lacutamab demonstrated significant symptom relief and quality of life improvements.
